Clinical trials for Blindness and vision loss

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Blindness and vision loss. For all clinical trials, go to clinical trials search

This list shows clinical trials for Blindness and vision loss

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Blindness and vision loss
Title Recruitment status Location
Causes of Visual Loss in Retinal Disease Recruiting United Kingdom
Continuous positive airway pressure (CPAP) in patients with impaired vision due to diabetic Retinopathy and concurrent Obstructive Sleep Apnoea (OSA): ROSA trial Recruiting United Kingdom
A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema Recruiting United Kingdom
CREATE - Children Reading With Electronic Assistance To Educate Recruiting United Kingdom
Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema Recruiting United Kingdom
A 12-month study to evaluate the efficacy and safety of injections of 0.5 mg ranibizumab into the eye of patients with vision loss caused by increased accumulation of fluid within the intraretinal layers of the macula (macular edema) and for which ranibizumab may have a positive impact Not Recruiting United Kingdom
A 12 month, phase III, randomized, double-masked, multi-center, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs. verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia Not Recruiting United Kingdom
Study of efficacy and safety of ranibizumab in patients with wet age related macular degeneration that have previously been treated with aflibercept. Not Recruiting United Kingdom
"Estudio Fase IIIb aleatorizado de dos años, simple ciego, multicéntrico y controlado, para evaluar la eficacia y seguridad de 0,5 mg de ranibizumab en dos algoritmos de tratamiento de tipo "tratar y extender" frente a 0,5 mg de ranibizumab según necesidad, en pacientes con edema macular y discapacidad visual secundarios a diabetes mellitus." // "A 2 year randomized, single-masked, multicenter, controlled phase IIIb trial assessing the Efficacy and safety of 0.5 mg ranibizumab in two "treat and extend" treatment algorithms vs. 0.5 mg ranibizumab as needed in patients with macular edema and visual Impairment secondary to diabetes mellitus." - RETAIN Not Recruiting United Kingdom
To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema Not recruiting United Kingdom

Page last reviewed: 08/07/2015

Next review due: 01/07/2018